InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,180.74
(
1.03%
)
US TECH 100
17,600.40
(
1.04%
)
Dow Jones
38,852.27
(
0.46%
)
Brent Oil
83.40
(
0.33%
)
Bitcoin
63,304.38
(
-1.09%
)
Post# of 251730
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119579
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: mcbio post# 188317

Wednesday, 09/28/2016 4:23:12 PM

Wednesday, September 28, 2016 4:23:12 PM

Post# of 251730
ENTA starts phase-1 trial of NASH compound, EDP-305:

http://finance.yahoo.com/news/enanta-pharmaceuticals-initiates-phase-1-201200159.html

EDP-305 is an FXR agonist—the same drug class as ICPT's OCA and GILD's GS-9674 (acquired from PFNX in 2015: #msg-109653984).

ENTA has asserted that EDP-305 is substantially more potent than ICPT's OCA—see slides 24, 26, &27 at http://jpmorgan.metameetings.com/confbook/healthcare16/stash/slides/19782/confbook_slideshow.php .

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up